Congenital long QT syndrome

Area of Science:

• Cardiology
• Genetics
• Molecular Biology

Background:

• Congenital long QT syndrome (LQTS) is a hereditary cardiac disease affecting 1 in 2,500 births.
• Characterized by QT interval prolongation and risk of life-threatening arrhythmias, syncopal episodes, cardiac arrest, and sudden cardiac death.
• Genetic basis involves mutations in cardiac ion channel genes, prolonging action potential duration.

Purpose of the Study:

• To summarize the understanding of congenital long QT syndrome (LQTS).
• To outline diagnostic criteria and current treatment strategies.
• To discuss prognosis and specific high-risk patient subgroups.

Main Methods:

• Review of genetic basis and identified LQTS genes (KCNQ1, KCNH2, KCNE1, KCNE2, CACNA1c, CAV3, SCN5A, SCN4B).
• Evaluation of diagnostic approaches, including electrocardiographic, clinical, familial, and molecular screening.
• Assessment of treatment modalities: beta-blockers, left cardiac sympathetic denervation (LCSD), and implantable cardioverter defibrillator (ICD) therapy.

Main Results:

• LQT1, caused by KCNQ1 gene mutations, is the most prevalent LQTS variant.
• Typical LQTS cases are diagnostically straightforward, but borderline cases require comprehensive evaluation.
• Treatment guidelines recommend beta-blockers as first-line therapy, with LCSD and ICD considered for refractory cases.

Conclusions:

• Accurate diagnosis and timely treatment significantly improve LQTS prognosis.
• Specific LQTS variants (Timothy syndrome, Jervell Lange-Nielsen syndrome with KCNQ1 mutations, LQT3 with 2:1 AV block) are associated with poorer outcomes.
• Ongoing research into genetic and clinical factors is crucial for personalized management.